Yarlagadda S. Babu
Net Worth

Last updated:

What is Yarlagadda S. Babu net worth?

The estimated net worth of Dr. Yarlagadda S. Babu is at least $16,205,301 as of 14 Nov 2022. He owns shares worth $2,451,022 as insider, has earned $2,832,359 from insider trading and has received compensation worth at least $10,921,920 in BioCryst Pharmaceuticals, Inc..

What is the salary of Yarlagadda S. Babu?

Dr. Yarlagadda S. Babu salary is $682,620 per year as Chief Discovery Officer in BioCryst Pharmaceuticals, Inc..

How old is Yarlagadda S. Babu?

Dr. Yarlagadda S. Babu is 72 years old, born in 1953.

What stocks does Yarlagadda S. Babu currently own?

As insider, Dr. Yarlagadda S. Babu owns shares in one company:

Company Title Shares Price per share Total value
BioCryst Pharmaceuticals, Inc. (BCRX) Chief Discovery Officer 298,541 $8.21 $2,451,022

What does BioCryst Pharmaceuticals, Inc. do?

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

BCRX logo
BCRX
BioCryst Pharmaceuticals, Inc.
$8.21

Yarlagadda S. Babu insider trading

BioCryst Pharmaceuticals, Inc.

Dr. Yarlagadda S. Babu has made 14 insider trades between 2009-2022, according to the Form 4 filled with the SEC. Most recently he sold 31,515 units of BCRX stock worth $437,428 on 14 Nov 2022.

The largest trade he's ever made was exercising 62,000 units of BCRX stock on 7 Dec 2021. As of 14 Nov 2022 he still owns at least 298,541 units of BCRX stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 31,515 $13.88 $437,428
Option
Emp. Stock Option (Right to Buy) 50,000 $1.42 $71,000
Option
Common Stock 50,000 $1.42 $71,000
Option
Common Stock 50,000 $1.42 $71,000
Sale
Common Stock 20,000 $17.16 $343,200
Sale
Common Stock 30,100 $12.2 $367,220
Option
Common Stock 62,000 $4.73 $293,260
Option
Emp. Stock Option (Right to Buy) 62,000 $4.73 $293,260
Option
Common Stock 50,000 N/A N/A
Option
Stock Option (Right to Buy) 50,000 N/A N/A
Purchase
Common Stock 25,000 $1.45 $36,250
Option
Non-Qualified Stock Option 19,686 $1.2 $23,623
Option
Common Stock 31,874 $1.2 $38,249
Option
Common Stock 30,000 $3.26 $97,800
Option
Non-Qualified Stock Option 20,622 $3.26 $67,228
Sale
Common Stock 30,000 $4.06 $121,800
Sale
Common Stock 12,105 $10.16 $122,987
Sale
Common Stock 37,400 $10.59 $396,066
Sale
Common Stock 10,495 $10.5 $110,198
Option
Non-Qualified Stock Option 2,208 $8.83 $19,497
Option
Common Stock 28,816 $7.32 $210,933
Sale
Common Stock 40,642 $12.57 $510,870
Option
Emp. Stock Option (Right to Buy) 23,179 $4.3 $99,670
Option
Common Stock 23,179 $4.3 $99,670
Sale
Common Stock 837 $4.78 $4,001
Option
Common Stock 53,668 $0.24 $12,666
Option
Emp. Stock Option (Right to Buy) 46,139 $0.39 $18,133
Option
Emp. Stock Option (Right to Buy) 29,686 $1.19 $35,326
Sale
Common Stock 30,912 $4.22 $130,449
Option
Common Stock 30,912 $1.14 $35,240
Sale
Common Stock 6,400 $10.85 $69,421
Sale
Common Stock 200 $10 $2,000
Sale
Common Stock 3,400 $10 $34,000
Sale
Common Stock 20,000 $9.14 $182,720

BioCryst Pharmaceuticals key executives

BioCryst Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: